Influenza A (H5N1) virus monovalent vaccine (GlaxoSmithKline)

N/A

Report date: 2026/05/12 09:09:26

Base Information

Drug NameInfluenza A (H5N1) virus monovalent vaccine (GlaxoSmithKline)

Drug Alias NameInfluenza A (H5N1) Virus Monovalent Vaccine, AdjuvantedGSK-5536522

ClassificationVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine > mRNA vaccineVaccines > Biological material > Viral vaccineVaccines > Application > Prophylactic vaccine +[4]

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsInfluenza A virus infectionsInfluenza, Human

Global Approved IndicationsInfluenza A virus infectionsInfluenza, Human

Approved Indications in ChinaN/A

Original Approved Country/TerritoryUnited States

Original Approved Date2013/11/22

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesGlaxosmithkline Plc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGlaxosmithkline Plc

Active IndicationsInfluenza A virus infectionsInfluenza, Human

Inactive IndicationsN/A

Other Information

ATC CodeJ07BB01